Takara Bio revises H1 forecasts, anticipates significant loss of 6.9 bn yen

Takara Bio now projects net sales of 18,700 million yen for H1 FY2026, a decrease of 2,600 million yen or 12.2% from previously announced forecasts. Operating profit is expected to decline by 900 million yen to a loss of 2,350 million yen, while ordinary profit is forecast to be a loss of 2,500 million yen, a 1,070 million yen decrease. Net income attributable to owners of the parent is now projected at a loss of 6,900 million yen, a significant 5,580 million yen reduction, with net income per share at a loss of 57.30 yen.

This revision is attributed to a global downturn in the life sciences research market, including reduced U.S. government research grants and China's economic recession, leading to decreased R&D activity. Despite efforts to lower SG&A expenses, the substantial impact of declining sales is expected to result in lower profits.

The company anticipates recording an extraordinary impairment loss of approximately 3.9 billion yen on expanded manufacturing facilities following the termination of a joint development agreement for NY-ESO-1 • siTCRTM gene therapy. Additionally, Takara Bio expects to reverse deferred tax assets by approximately 400 million yen in Q2 FY2026.